Business Context and Reporting Period
This Form 8-K is a current report filed by Pluri Inc. (formerly Pluristem Therapeutics Inc.) on July 25, 2022, regarding events occurring on July 22, 2022. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Global Market under the symbol "PLUR".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and branding changes.
Material Changes
- Legal Name Change: Effective July 26, 2022, the Company completed a legal name change from "Pluristem Therapeutics Inc." to "Pluri Inc." via a merger with a wholly-owned subsidiary.
- Corporate Charter: The Company amended its Amended and Restated Articles of Incorporation to reflect the new name. No other changes to the Charter were made.
- Trading Symbol: As of the opening of trading on July 26, 2022, the ticker symbol on The Nasdaq Global Market changed to "PLUR" (CUSIP: 72942G 104).
Guidance, Outlook, and Management Commentary
The filing references a press release issued on July 25, 2022, which includes a letter from Chief Executive Officer Yaky Yanay. However, the text of this letter and specific details regarding future guidance, outlook, or risks are not included in the provided filing content.
Investor Verification Checklist
- Verify the effective date of the name change (July 26, 2022) and the new ticker symbol "PLUR" on trading platforms.
- Review the attached Exhibit 99.1 (Press Release) for the full text of the CEO's letter and any strategic context not detailed in the 8-K.
- Confirm that the CUSIP number 72942G 104 is correctly updated in brokerage accounts.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.